ArticleRheumatology and immunology research2026
Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China.
Article in Rheumatology and immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Secukinumab (SEC), an interleukin 17A inhibitors (IL-17Ai) has been shown to be effective in managing axial spondyloarthritis (axSpA). However, data on its long-term retention in Chinese populations remain limited. This study aims to evaluate the retention rate of SEC in axSpA and its predisposing factors in Chinese patients. Methods: We conducted a retrospective cohort study across three centers, including axSpA patients treated with SEC. Prescription records were retrieved from the hospital information system (HIS) and electronic medical records were reviewed to confirm diagnoses and treatment exposures. Retention rates at 12, 24, and 36 months were estimated using Kaplan-Meier analysis. Cox proportional hazards regression assessed the impact of prior biologic therapy and dosage on discontinuation risk. Discontinuation events were also evaluated. Result: A total of 459 patients were identified and included, with the longest treatment follow-up period reaching 42 months. The overall drug retention rates for SEC were 76.1%, 68.7%, and 62.8% at 12, 24, and 36 months, respectively. Biologics-naïve patients exhibited a higher 12-month retention rate (80.7%) compared to biologic-experienced patients (72.5%). Among biologic-experienced patients, the 12-month retention rates progressively decreased with an increasing number of prior biologics: 74.6% for one prior biologic, 72.0% for two, and 55.3% for three. No statistically significant difference in retention rate was observed between the 300 mg and 150 mg groups ( Conclusion: SEC demonstrates robust retention rates in this Chinese axSpA cohort, particularly among biologics-naïve patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.